Michel Michaelides, MD, FACP, on Gene Therapy's Potential in Retinitis Pigmentosa
The professor of ophthalmology at the University College London Institute of Ophthalmology discussed the likely rise of gene therapies in inherited retinal diseases.
Devon J. Shedlock, PhD, on Shifting from Autologous to Allogeneic Therapies
The chief scientific officer of cell therapy at Poseida Therapeutics discussed the company’s CAR-T and TCR technologies.
Deyaa Adib, MD, on Optimizing Manufacturing of Solid Tumor Cell Therapies
The chief medical officer of Triumvira Immunologics discussed the company’s future plans.
Roberto Giugliani, MD, PhD, on Advantages of Gene Therapy in MPS Type 2
The professor of genetics at Federal University of Rio Grande do Sul discussed how RGX-121 has the potential to change the treatment landscape of MPSII.
Nick Boyle, PhD, on Advantages of In Vivo CAR Therapies
The chief executive officer of Abintus Bio discussed the company’s in vivo approach and how it could help expand patient access to cell therapies.
Clive Svendsen, PhD, on Astrocyte Progenitor Cell Therapy in ALS
The director of the Regenerative Medicine Institute at Cedars Sinai discussed results from a phase 1/2a study of CNS10-NPC-GDNF.
Evan Zynda, PhD, on Optimizing Manufacturing to Increase Access to Cell Therapy
The senior scientist at Thermo Fisher Scientific discussed the company’s approach to scaling and strategic partnerships.
Samir Parekh, MD, on Investigating Treatment Options for Relapsed Myeloma
The director of translational research in myeloma at the Tisch Cancer Institute discussed investigating sequential T cell redirection therapies.
Treating Autoimmune Diseases With Smarter Cell Therapies
Karen Walker, chief technology officer, Kyverna Therapeutics, discussed the company’s CAR T-cell and regulatory T-cell technologies.
Christine Coughlin, MD, PhD, on TRACK-NK Technology in Non-Small Cell Lung Cancer
The chief executive officer of Cytoimmune discussed the company’s technology platforms and programs.
Sid Kerkar, MD, on Developing CAR T Therapies Without Lymphodepletion Chemotherapy
The vice president of oncology and research and development at Exuma Biotech discussed the company’s platforms, including CAR-TaNK cells.
Working With the Community to Improve Patient Access to Trials, Therapies
Rob Richards, administrative director, cell therapy and transplant, University of Pennsylvania, discussed improving reach of gene therapy trials and therapies.
Leaping the Next Hurdle in CAR T-Cell Therapies
Phil Cyr, Senior Vice President, Precision Value & Health, discussed challenges to tackle with CAR T-cell therapies.
Optimizing CAR T Therapies for Gastric Cancer
Hong Ma, senior vice president, clinical development, cancer immunotherapy, CARSgen, discussed data from a phase 1 trial of CT041.
Deyaa Adib, MD, on Safety Advantages of TAC T-Cell Therapy in Solid Tumors
The chief medical officer of Triumvira Immunologics discussed how TAC01-HER2 could address unmet needs in treating solid tumors.
Jeffrey Miller, MD, on Emerging Research With Natural Killer Cells
The deputy director of the Masonic Cancer Center discussed trends of presentations from ESMO 2022.
Roberto Giugliani, MD, PhD, on Reducing GAGs in MPS Type 2 With Gene Therapy
The professor of genetics at Federal University of Rio Grande do Sul discussed updated data from the CAMPSIITE trial.
Deyaa Adib, MD, on Evaluating HER2 TAC T-Cell Therapy in Solid Tumors
The chief medical officer of Triumvira Immunologics discussed updates from the TACTIC-2 study presented at ESMO Congress 2022.
Jeffrey Miller, MD, on Engaging NK Cells in Solid Tumors
The deputy director of the Masonic Cancer Center discussed the preclinical findings of his study on a TriKE engager and NK cells.
David S. Hong, MD, on the SURPASS Clinical Trial and TCR T-cell Therapy in Solid Tumors
Hong presented data from the SURPASS clinical trial at the 2022 European Society for Medical Oncology (ESMO) Congress.
Weijia Fang, MD, and Guoqiang Ai, MD, on the Future of IMC001 in Gastric and Colorectal Cancer
Fang commented on a limitation of the clinical trial pointed out at the European Society for Medical Oncology (ESMO) 2022 Congress.
Weijia Fang, MD, and Tianhang Luo, MD, on EpCAM-Targeted CAR-T Therapy in Advanced Colorectal and Gastric Cancer
Fang recently presented at the European Society for Medical Oncology (ESMO) 2022 Congress.
Noopur Raje, MD, on bb21217 Data in R/R Multiple Myeloma
The director, Center for Multiple Myeloma, Massachusetts General Hospital, discussed data seen with bb21217 in R/R MM.
Adam D. Cohen, MD, on Cilta-Cel for Lenalidomide-Refractory Multiple Myeloma
The director of myeloma immunotherapy at University of Pennsylvania discussed cilta-cel's efficacy in lenalidomide-refractory multiple myeloma.
Mark Forman, MD, PhD, on Genetic Testing and Further Research in Frontotemporal Dementia
The chief medical officer of Passage Bio discussed research needs in FTD.
Developing a Safer Allogeneic Cell Therapy for Ovarian Cancer
Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed AVB-001's lower systemic toxicity profile seen in preclinical studies.
Alexis Thompson, MD, MPH, on the Impact of Beti-Cel's Approval in Beta Thalassemia
The primary investigator and chief of hematology at Children’s Hospital of Philadelphia discussed the collaboration and research that went into developing beti-cel.
Mark Forman, MD, PhD, on ICM Administration of Gene Therapy in Frontotemporal Dementia
The chief medical officer of Passage Bio discussed the phase 1/2 upliFT-D study of PBFT02.
Developing a More Precise Allogeneic Cell Therapy for Ovarian Cancer
Michael Heffernan, chairman and chief executive officer, Avenge Bio, discussed the IND clearance of AVB-001 and the soon-to-initiate phase 1 trial.
Irene Agodoa, MD, on Addressing GVHD Risks in Treating Hematologic Malignancies
The senior vice president and head of medical affairs at Orca Bio discussed how Orca-T has been developed to lower the risk of graft-versus-host disease.
